Last reviewed · How we verify
Naldebain
At a glance
| Generic name | Naldebain |
|---|---|
| Also known as | Placebo A + Tween20 and PEG400, Naldebain ER®, Sebacoyl Dinalbuphine Ester Injection |
| Sponsor | Sinew Pharma Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Postoperative Pain Management of Therapeutic Surgery: a Prospective, Observational Cohort Study.
- Dinalbuphine Sebacate in Postoperative Pain Control After TKA (PHASE4)
- Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section (PHASE2, PHASE3)
- Postoperative Pain Management of Caesarean Section
- PO Pain Management With Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery (PHASE4)
- Postoperative Pain Management on Patients Undergoing Lung Tumor Resection
- Naldebain and Video-assisted Thoracoscopic Surgery (PHASE4)
- Combined Use of Naldebain® ER Injection and Precedex® After VATS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naldebain CI brief — competitive landscape report
- Naldebain updates RSS · CI watch RSS
- Sinew Pharma Inc. portfolio CI